Expanded capacity Piramal Pharma Solutions has recent facility expansions including a new spray drying suite at the peptide facility in Turbhe, India and additional capabilities in Riverview, Michigan, signaling increased capacity for high-potency peptides, spray-dried APIs, and sterile fill/finish. This creates opportunities to position PPS as a scalable CDMO partner for growing biotech clients and legacy pharma companies needing larger output without switching providers.

Advanced manufacturing The launch of an advanced spray drying suite and payload-linker development and manufacturing capabilities at multiple sites indicates PPS is advancing with specialized, high-containment and complex manufacturing. Sales prospects include partners requiring potent API processing, payload-linker constructs, and advanced solid or peptide formulations for niche therapies and ADCs.

Global footprint With a globally integrated network spanning North America, Europe, and Asia and a commercial reach in over 100 countries, PPS offers geographic flexibility for multinational clients seeking regional development and manufacturing, supply chain resilience, and easier regulatory alignment across markets.

Financial stability A revenue range of 500 million to 1 billion USD and expansion investments demonstrate financial capability to undertake long-cycle development programs, large-scale manufacturing transfers, and sustained clinical and commercial supply projects, making PPS a credible partner for large and mid-sized pharma players.

Strategic partnerships Recent collaborations and plant enhancements, including partnerships like the Botanix alliance and expanded capacity for peptide and ADC-related services, indicate PPS actively pursues strategic programs across discovery, development, and commercial manufacturing, presenting cross-sell opportunities across API, finished dosage forms, sterile manufacturing, and specialized high-potency services.